# S4 Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/s4-medical

- Industry: Medical Devices & Equipment
- Headquarters: Cleveland, US
- Website: www.s4medical.com
- Total disclosed funding: $4M
- Latest round: Series A (Apr 2, 2021)
- Investors on record: 7

## About

S4 Medical Corp. specializes in developing innovative medical devices, focusing on enhancing safety during catheter ablation procedures for atrial fibrillation. Their flagship product, the esolution device, is the first FDA-cleared technology of its kind.Founded in 2017 in Cleveland, US, S4 Medical Corp. is dedicated to improving cardiovascular care through its unique medical technology. The company has successfully completed 8 deals, with a focus on the development of its esolution device, which received its first funding in 2023. Richard Witismann, the founder, has a history of entrepreneurial endeavors in the medical technology field. The most recent funding round, Series B, raised USD 5.76 mn, equaling the total amount raised to date.S4 Medical's primary product is the esolution device, the first FDA-cleared technology designed specifically to deviate the esophagus during catheter ablation procedures for atrial fibrillation (AF). The device's innovative bilateral deviation accommodates varying pulmonary vein anatomies and lesion strategies, significantly reducing the risk of esophageal injury, which can affect up to 47% of AF ablation patients. It is compatible with all ablation energy sources, temperature probes, and mapping systems, allowing for streamlined procedures without the need for additional hardware. The company's clients primarily include hospitals and electrophysiology clinics in the United States and Europe.S4 Medical generates revenue through direct sales of its esolution device to healthcare institutions and electrophysiology practices, selling the device on a per-unit basis. As a critical component in catheter ablation workflows, the esolution is designed to facilitate its adoption in clinical settings where AF treatment is prevalent. Revenue is primarily realized through transactions with healthcare providers, emphasizing a B2B model that fosters long-term relationships aimed at enhancing procedural outcomes and ensuring continued use of its technology.In June 2023, S4 Medical Corp. raised USD 5.76 mn in Series B funding, which will be utilized to support regulatory approval processes in the US and Europe, aid in future product commercial launches, and improve manufacturing capabilities. The company plans to expand into new markets, specifically targeting additional regions within Europe and expanding its footprint in the US healthcare system. Upcoming product developments are anticipated, although specific details on new launches have yet to be disclosed.

## Funding rounds

- Series A, Apr 2, 2021, $3M — Ohio Innovation Fund, JumpStart, JobsOhio, Angel Physicians Fund
- Seed, Aug 24, 2018 — Valley Growth Ventures
- Seed, Apr 5, 2018, $1M — JumpStart, North Coast Ventures, ProMedica Innovations

## Investors

- JumpStart (https://capitalatlas.ai/funds/jumpstart) — Seed, Series A
- North Coast Ventures (https://capitalatlas.ai/funds/north-coast-ventures) — Seed
- ProMedica Innovations — Seed
- Valley Growth Ventures (https://capitalatlas.ai/funds/valley-growth-ventures) — Seed
- Ohio Innovation Fund (https://capitalatlas.ai/funds/ohio-innovation-fund) — Series A
- JobsOhio (https://capitalatlas.ai/funds/jobsohio) — Series A
- Angel Physicians Fund (https://capitalatlas.ai/funds/angel-physicians-fund) — Series A